Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of
mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of
transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of
Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of
acute kidney rejection only. There is no clinical data of its use in heart transplant
patients.